In a patient with a severe infection whose isolate is susceptible to meropenem and imipenem, should ertapenem still be used?

Should Ertapenem Be Used When Isolate is Susceptible to Meropenem and Imipenem?

No, you should not use ertapenem when in vitro susceptibility testing confirms the isolate is susceptible to meropenem and imipenem—switch to meropenem or imipenem for definitive therapy. 1

Rationale for Carbapenem Selection Based on Susceptibility Data

When culture and susceptibility results become available, antimicrobial stewardship principles mandate tailoring therapy to the narrowest effective spectrum 2. The key distinction lies in understanding that ertapenem lacks activity against Pseudomonas aeruginosa and has reduced activity against certain resistant organisms compared to meropenem/imipenem 3.

When Ertapenem is Appropriate:

• Empiric therapy for community-acquired infections of mild-to-moderate severity 2
• Confirmed ESBL-producing Enterobacterales without septic shock 1
• Step-down targeted therapy after clinical improvement, when susceptibility is confirmed 1
• Once-daily dosing advantage for outpatient parenteral therapy 3

When to Switch to Meropenem/Imipenem:

If your isolate is susceptible to meropenem/imipenem, these agents should be preferred because:

1. Antimicrobial stewardship concerns: The 2010 IDSA/SIS guidelines explicitly state concern that "broad use of ertapenem may hasten the appearance of carbapenem-resistant Enterobacteriaceae, Pseudomonas, and Acinetobacter species" 2. Reserving ertapenem for specific indications helps preserve other carbapenems for severe infections 1.

2. Spectrum considerations: If susceptibility testing shows meropenem/imipenem sensitivity, this indicates the organism does not have high-level carbapenem resistance mechanisms. Meropenem and imipenem provide broader coverage and are the preferred agents for severe infections 2.

3. Severe illness: For patients with severe physiologic disturbance, septic shock, or high mortality risk, meropenem or imipenem are explicitly recommended over ertapenem 2, 4. The 2023 ESCMID guidelines state: "for BSIs without septic shock ertapenem may be preferred to imipenem or meropenem," but this is a conditional recommendation only when other carbapenems are being reserved 1.

Clinical Algorithm for Carbapenem Selection

Step 1: Assess infection severity

• Mild-to-moderate community-acquired infection → Consider ertapenem empirically
• Severe infection, septic shock, or healthcare-associated → Use meropenem/imipenem empirically

Step 2: Review susceptibility results

• If susceptible to meropenem/imipenem → Switch to meropenem or imipenem
• If resistant to meropenem/imipenem but susceptible to ertapenem (EORE pattern) → Continue ertapenem 5

Step 3: Consider stewardship principles

• Limit carbapenem use when alternatives are available 1, 6
• Reserve ertapenem for ESBL-producing organisms or step-down therapy 1
• Use meropenem/imipenem for documented susceptibility in severe infections

Common Pitfalls

Pitfall 1: Continuing ertapenem empirically started therapy when susceptibilities show meropenem/imipenem sensitivity. This wastes the stewardship advantage of ertapenem and doesn't optimize therapy.

Pitfall 2: Using ertapenem in critically ill patients with hypoalbuminemia. While recent data suggest it may be acceptable 7, meropenem remains preferred for severe infections with proven susceptibility.

Pitfall 3: Assuming all carbapenems are interchangeable. Ertapenem has a 4-hour half-life allowing once-daily dosing, but lacks anti-pseudomonal activity 3, 8. If Pseudomonas is a concern, meropenem/imipenem must be used.

Dosing When Meropenem/Imipenem is Selected

• Meropenem: 1 g IV every 8 hours 2
• Imipenem-cilastatin: 500 mg IV every 6 hours or 1 g every 8 hours 2
• Ertapenem (if appropriate): 1 g IV every 24 hours 2, 9

For severe infections or undrained abscesses, maximize β-lactam dosing 2.